Overview

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MTRX1011A in Patients With Rheumatoid Arthritis

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase I multicenter study that will be conducted in the United States and consists of a double-blind, placebo-controlled, SAD stage, followed by a double-blind, placebo controlled MAD stage. The study will be conducted in approximately 65 adult patients between 18 and 80 years old who have RA.
Phase:
Phase 1
Details
Lead Sponsor:
Genentech, Inc.